OMCL - Omnicell, Inc.
| Previous Close | 85.17 |
| Open | 85.40 |
| Bid | 85.30 x 800 |
| Ask | 85.46 x 1100 |
| Day's Range | 84.70 - 86.06 |
| 52 Week Range | 41.25 - 86.06 |
| Volume | 105,453 |
| Avg. Volume | 360,600 |
| Market Cap | 3.377B |
| Beta (3Y Monthly) | 1.45 |
| PE Ratio (TTM) | 91.65 |
| EPS (TTM) | 0.93 |
| Earnings Date | Apr 24, 2019 - Apr 29, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 76.88 |
- GlobeNewswire•3 days ago
Factors of Influence in 2019, Key Indicators and Opportunity within Procter & Gamble, Hertz Global, NN, Omnicell, BioDelivery Sciences International, and Movado Group — New Research Emphasizes Economic Growth
NEW YORK, Feb. 19, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Simply Wall St.•11 days ago
Need To Know: Omnicell, Inc. (NASDAQ:OMCL) Insiders Have Been Selling Shares
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! It is not uncommon to see companiesRead More...
- PR Newswire•11 days ago
Omnicell to Feature Vision for Fully Digitized, Autonomous Pharmacy at HIMSS19
Technology, Intelligence, and Expert Services Showcased in Booth #2071 Designed to Address Rising Medication Management Costs MOUNTAIN VIEW, Calif. , Feb. 11, 2019 /PRNewswire/ -- Omnicell, Inc., (NASDAQ: ...
- Thomson Reuters StreetEvents•11 days ago
Edited Transcript of OMCL earnings conference call or presentation 7-Feb-19 9:30pm GMT
Q4 2018 Omnicell Inc Earnings Call
- Zacks•14 days ago
Omnicell (OMCL) Q4 Earnings Beat Estimates, Revenues Miss
Omnicell (OMCL) steadily benefits from product introductions, strategic alliances and digital conversions.
Motley Fool•15 days agoOmnicell Inc (OMCL) Q4 2018 Earnings Conference Call Transcript
OMCL earnings call for the period ending December 31, 2018.
- Zacks•15 days ago
Omnicell (OMCL) Q4 Earnings Surpass Estimates
Omnicell (OMCL) delivered earnings and revenue surprises of 4.48% and -1.35%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
GuruFocus.com•15 days agoCerner: Latest Results and Big Investment Group Signal It's a Buy
Investors seeking stocks to short may want to look closely at the companies in health care information technology. Warning! GuruFocus has detected 2 Warning Sign with CERN. Although the report didn't cite companies, maybe one of candidates trading higher than warranted is Cerner Corp. (CERN).
- Associated Press•15 days ago
Omnicell: 4Q Earnings Snapshot
On a per-share basis, the Mountain View, California-based company said it had net income of 36 cents. Earnings, adjusted for one-time gains and costs, came to 70 cents per share. The results beat Wall ...
- PR Newswire•15 days ago
Omnicell Reports Results for Fiscal Year and Fourth Quarter 2018
Record yearly GAAP revenues of $787.3 million Record yearly Non-GAAP revenues of $787.3 million 2018 GAAP net income per diluted share of $0.93 Record 2018 Non-GAAP net income per diluted share of $2.09 ...
- Zacks•18 days ago
Omnicell Solid on Geographic Expansion Amid Stiff Competition
Omnicell (OMCL) gains from expanding into new markets. Stiff rivalry is a concern.
- PR Newswire•18 days ago
Omnicell's Automated Medication Dispensing System Receives Top KLAS Award for the 13th Consecutive Year
Company Also Sweeps Category Leader Designations for Central Pharmacy Automation Hardware MOUNTAIN VIEW, Calif. , Feb. 4, 2019 /PRNewswire/ -- Omnicell, Inc. , (NASDAQ: OMCL), has earned top honors in ...
- PR Newswire•21 days ago
Omnicell to Release Fourth Quarter 2018 Earnings Results on February 7, 2019
MOUNTAIN VIEW, Calif. , Feb. 1, 2019 /PRNewswire/ -- Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication and supply management solutions and adherence tools for healthcare systems and pharmacies, ...
- Zacks•22 days ago
Omnicell (OMCL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks•23 days ago
Illumina (ILMN) Q4 Earnings Lag Estimates, Revenues Top Mark
Illumina's (ILMN) Q4 figures show a sturdy uptick in sequencing consumable revenues.
- PR Newswire•23 days ago
Texas Children's Hospital Expands Partnership with Omnicell
According to an American Society of Health-system Pharmacists national survey, pharmacy directors estimate that 76 percent of staff time is spent on non-clinical activities.1 An automated medication management infrastructure empowers pharmacists, nurses, clinicians, and pharmacy staff to focus on patient and clinician satisfaction, leading to improved patient care, fewer errors, enhanced safety, and new opportunities for growth. "As our health system continues to expand, we are constantly striving for excellence in care across our facilities," said Gee Mathen, assistant director of Pharmacy Applications and Technical Services at Texas Children's Hospital.
- Zacks•24 days ago
Thermo Fisher (TMO) Down on Business Divestment Declaration
Thermo Fisher's (TMO) Anatomical Pathology business comes under its Specialty Diagnostics segment catering to customers at healthcare and clinical laboratories.
- Zacks•24 days ago
Here's Why You Should Snap Up Abbott (ABT) Stock Right Now
We are optimistic about the strong and consistent performance of Abbott's (ABT) EPD segment. The company's Diabetes Care business has been hogging the limelight on strength in FreeStyle Libre.
- Zacks•last month
CVS Health's PBM Pharmacy Platform to Ride on Walmart Deal
Per the terms of the deal between CVS Health (CVS) and Walmart, the latter will continue to take part in the CVS Caremark PBM commercial and Managed Medicaid retail pharmacy networks.
- Zacks•last month
Neogen Gains on Strong Genomic Arm Amid Stiff Competition
Neogen's (NEOG) genomic business shows steady growth on acquisitions in Australia and Brazil. Stiff rivalry a cause of concern.
- Zacks•last month
Why You Should Consider Buying Omnicell (OMCL) Stock Now
Omnicell (OMCL) is pulling out all the stops to strengthen the medication adherence segment.
- Simply Wall St.•last month
What Does Omnicell, Inc.’s (NASDAQ:OMCL) Share Price Indicate?
Omnicell, Inc. (NASDAQ:OMCL), which is in the healthcare services business, and is based in United States, saw a double-digit share price rise of over 10% in the past couple of Read More...
- Benzinga•2 months ago
Pivotal Updates Ad Agencies Ahead of Q4 Earnings
Multiple ad agencies are facing concerns mostly due to the disruptions their core customers face. But at today's valuations, most ad stocks are fully pricing in concerns, according to Pivotal Research ...
- Zacks•2 months ago
Omnicell (OMCL) Rides on Innovation Despite Cost Concerns
Omnicell (OMCL) steadily sees a solid uptake of Omnicell XT. It also strikes various deals for the XR2 and IVX Workflow products.
- PR Newswire•2 months ago
Omnicell To Present At The 37th Annual J.P. Morgan Healthcare Conference
MOUNTAIN VIEW, Calif. , Dec. 27, 2018 /PRNewswire/ -- Omnicell, Inc. (NASDAQ:OMCL), a leading provider of medication and supply management solutions and adherence tools for healthcare systems and pharmacies, ...
